Drug Use Investigation for Toviaz

NCT01936870

Last updated date
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Overactive Bladder (OAB)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients prescribed fesoterodine (Toviaz).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- There are no exclustion criteria

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Overactive Bladder (OAB)Drug Use Investigation for Toviaz
NCT01936870
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Overactive Bladder (OAB)Detrol LA In Men With Overactive Bladder.
NCT00282932
  1. Anaheim, California
  2. La Mesa, California
  3. Aurora, Colorado
  4. Iowa City, Iowa
  5. Shreveport, Louisiana
  6. Watertown, Massachusetts
  7. Westampton, New Jersey
  8. New York, New York
  9. Cincinnati, Ohio
  10. State College, Pennsylvania
  11. Houston, Texas
  12. Calgary, Alberta
  13. Surrey, British Columbia
  14. Victoria, British Columbia
  15. Kingston, Ontario
  16. London, Ontario
  17. Oakville, Ontario
  18. Toronto, Ontario
  19. Toronto, Ontario
  20. Toronto, Ontario
  21. Montreal, Quebec
  22. Montreal, Quebec
  23. Pointe-Claire, Quebec
  24. Aalborg,
  25. Herlev,
  26. Nykobing Falster,
  27. Berlin,
  28. Duisburg,
  29. Frankfurt,
  30. Muelheim A.d. Ruhr,
  31. Muenchen,
  32. Muenchen,
  33. Rosenheim,
  34. Starnberg,
  35. Latina,
  36. Padova,
  37. Bucheon-si, Gyunggi-do
  38. Busan,
  39. Seoul,
  40. Seoul,
  41. Guadalajara, Jalisco
  42. Zapopan, Jalisco
  43. Tlalpan, México DF
  44. Durango,
  45. Durango,
  46. Bodø,
  47. Moelv,
  48. Bratislava,
  49. Kosice,
  50. Malacky,
  51. Martin,
  52. Skalica,
  53. Bloemfontein, Free State
  54. Bloemfontein, Free State
  55. Parktown, Gauteng Province
  56. Durban, Kwa Zulu Natal
  57. Pietermaritzburg, Kwa Zulu Natal
  58. Cape Town,
  59. A Coruna, A Coruña
  60. Palma de Mallorca, Islas Baleares
  61. Barcelona,
  62. Granada,
  63. Madrid,
  64. Madrid,
  65. Valencia,
  66. Boras,
  67. Huskvarna,
  68. Lund,
  69. Skovde,
  70. Hualien,
  71. Kaohsiung,
  72. Taipei,
  73. Taipei,
  74. Adana,
  75. Istanbul,
  76. Izmir,
  77. Sihhiye-Ankara,
  78. Bristol, Avon
  79. Crewe, Cheshire
  80. Taunton, Somerset
  81. London,
Male
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Drug Use Investigation for Toviaz
Official Title Drug Use Investigation For Toviaz
Brief Summary The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients prescribed fesoterodine (Toviaz) by investigators involved in protocol A0221096.
Condition Overactive Bladder (OAB)
Intervention Drug: Fesoterodine (Toviaz)
Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
Study Groups/Cohorts Fesoterodine (Toviaz)
Intervention: Drug: Fesoterodine (Toviaz)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: August 10, 2016)
2521
Original Estimated Enrollment
 (submitted: September 3, 2013)
2000
Actual Study Completion Date May 2016
Actual Primary Completion Date May 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients prescribed fesoterodine (Toviaz).

Exclusion Criteria:

  • There are no exclustion criteria
Sex/Gender
Sexes Eligible for Study:All
Ages 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT01936870
Other Study ID Numbers A0221096
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2017